Literature DB >> 2535933

The reaction of 5-amino-salicylic acid with hypochlorite. Implications for its mode of action in inflammatory bowel disease.

J G Williams1, M B Hallett.   

Abstract

Although 5-amino-salicylic acid (5-ASA) provides effective treatment for inflammatory bowel disease, its mode of action is unestablished. 5-ASA inhibits luminol-dependent chemiluminescence triggered by activated neutrophils, hydrogen peroxide plus peroxidase or sodium hypochlorite. The concentrations required for 50% inhibition of the cells was approximately 3.6 microM. In the non-cellular system, the concentration of 5-ASA required for total inhibition being approximately equivalent to concentration of sodium hypochlorite. The reaction of 5-ASA with hypochlorite or activated neutrophils resulted in the production of a non-fluorescent product of 5-ASA. The production of this metabolite by cells was dependent upon the activity of the peroxidase and occurred with a time course which was coincident with oxygen consumption. It was concluded that by reacting with hypochlorite, 5-ASA would provide protection against the potentially damaging effects of activated neutrophils in the inflamed bowel.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535933     DOI: 10.1016/0006-2952(89)90161-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 2.  Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment.

Authors:  J G Williams
Journal:  Ann R Coll Surg Engl       Date:  1990-07       Impact factor: 1.891

3.  5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells.

Authors:  S M McKenzie; W F Doe; G D Buffinton
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

4.  Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease.

Authors:  B Sido; V Hack; A Hochlehnert; H Lipps; C Herfarth; W Dröge
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 5.  Circulating neutrophils from patients with ulcerative colitis have a normal respiratory burst.

Authors:  J M Haydek; A Keshavarzian
Journal:  Inflammation       Date:  1995-12       Impact factor: 4.092

Review 6.  Inflammatory bowel disease management. Some thoughts on future drug developments.

Authors:  J Rhodes; G Thomas; B K Evans
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

7.  Induction of colitis in rats by 2-2'-azobis(2-amidinopropane) dihydrochloride.

Authors:  H Tamai; S Levin; T S Gaginella
Journal:  Inflammation       Date:  1992-02       Impact factor: 4.092

8.  Maintenance of α(1)-antitrypsin activity by means of co-application of hypochlorous acid-scavengers in vitro and in the supernatant of polymorphonuclear leukocytes: as a basis for a new drug delivery approach.

Authors:  Maria Schönberg; Uta Reibetanz; Sophie Rathmann; Jacqueline Lessig
Journal:  Biomatter       Date:  2012 Jan-Mar

9.  Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors.

Authors:  A K Banerjee; T J Peters
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

10.  Synergic modulation of the inflammatory state of macrophages utilizing anti-oxidant and phosphatidylserine-containing polymer-lipid hybrid nanoparticles.

Authors:  Md Zahangir Hosain; Kazuki Yuzuriha; Masafumi Takeo; Akihiro Kishimura; Yoshihiko Murakami; Takeshi Mori; Yoshiki Katayama
Journal:  Medchemcomm       Date:  2017-06-02       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.